iCAD (NASDAQ:ICAD) Rating Lowered to “Sell” at StockNews.com

iCAD (NASDAQ:ICAD) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

iCAD Stock Performance

iCAD stock opened at $1.79 on Wednesday. The firm has a market cap of $47.37 million, a price-to-earnings ratio of -16.91 and a beta of 1.47. iCAD has a 52-week low of $1.18 and a 52-week high of $2.65. The firm has a 50 day moving average price of $1.70 and a two-hundred day moving average price of $1.54.

iCAD (NASDAQ:ICAD) last announced its earnings results on Tuesday, August 13th. The technology company reported ($0.07) earnings per share for the quarter. The firm had revenue of $5.03 million for the quarter. iCAD had a negative return on equity of 13.59% and a negative net margin of 15.67%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Essex LLC acquired a new stake in iCAD during the third quarter worth approximately $216,000. First Eagle Investment Management LLC grew its position in shares of iCAD by 3.2% during the 1st quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company’s stock worth $1,129,000 after buying an additional 22,000 shares during the period. Perritt Capital Management Inc increased its stake in shares of iCAD by 14.2% in the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after acquiring an additional 19,917 shares in the last quarter. Perritt Capital Management Inc. lifted its position in shares of iCAD by 7.5% during the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after acquiring an additional 9,717 shares during the period. Finally, Virtu Financial LLC boosted its stake in iCAD by 55.6% during the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock worth $34,000 after acquiring an additional 7,604 shares in the last quarter. 24.61% of the stock is owned by institutional investors and hedge funds.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.